US5831002A
(en)
*
|
1992-05-20 |
1998-11-03 |
Basf Aktiengesellschaft |
Antitumor peptides
|
US5599902A
(en)
*
|
1994-11-10 |
1997-02-04 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Cancer inhibitory peptides
|
US5807984A
(en)
*
|
1995-11-09 |
1998-09-15 |
Basf Aktienegesellschaft |
Oligopeptides, the preparation and use thereof
|
US20010009901A1
(en)
*
|
1996-12-11 |
2001-07-26 |
Basf Aktiengesellschaft Germany |
Antineoplastic peptides
|
US5939527A
(en)
*
|
1996-07-30 |
1999-08-17 |
Basf Aktiengesellschaft |
Tetrapeptides as antitumor agents
|
US5741892A
(en)
*
|
1996-07-30 |
1998-04-21 |
Basf Aktiengesellschaft |
Pentapeptides as antitumor agents
|
US6239104B1
(en)
|
1997-02-25 |
2001-05-29 |
Arizona Board Of Regents |
Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
|
US5965537A
(en)
*
|
1997-03-10 |
1999-10-12 |
Basf Aktiengesellschaft |
Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
|
US6103698A
(en)
*
|
1997-03-13 |
2000-08-15 |
Basf Aktiengesellschaft |
Dolastatin-15 derivatives in combination with taxanes
|
US6143721A
(en)
*
|
1997-07-18 |
2000-11-07 |
Basf Aktiengesellschaft |
Dolastatin 15 derivatives
|
US6015790A
(en)
*
|
1997-10-06 |
2000-01-18 |
Basf Aktiengesellschaft |
Methods and compositions for treating rheumatoid arthritis
|
CA2315230C
(en)
*
|
1998-01-09 |
2004-06-29 |
Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University |
Anti-cryptococcal peptides
|
US5985837A
(en)
*
|
1998-07-08 |
1999-11-16 |
Basf Aktiengesellschaft |
Dolastatin 15 derivatives
|
CA2385528C
(en)
|
1999-10-01 |
2013-12-10 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
US20020022040A1
(en)
*
|
2000-07-10 |
2002-02-21 |
The Proctor & Gamble Company |
Methods of enhancing delivery of oil-soluble skin care actives
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
US7256257B2
(en)
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
ES2556641T3
(es)
*
|
2002-07-31 |
2016-01-19 |
Seattle Genetics, Inc. |
Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa
|
ES2457538T3
(es)
|
2003-02-20 |
2014-04-28 |
Seattle Genetics, Inc. |
Conjugados de anticuerpo anti-CD70-fármaco y su uso para el tratamiento de cánder y trastornos inmunológicos
|
SG195524A1
(en)
|
2003-11-06 |
2013-12-30 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
DK1827492T3
(da)
|
2004-11-30 |
2010-11-22 |
Curagen Corp |
Antistoffer rettet mod GPNMB og anvendelser deraf
|
CA2605507C
(en)
|
2005-04-19 |
2016-06-28 |
Seattle Genetics, Inc. |
Humanized anti-cd70 binding agents and uses thereof
|
US7772177B2
(en)
|
2005-05-18 |
2010-08-10 |
Aegera Therapeutics, Inc. |
BIR domain binding compounds
|
US8871720B2
(en)
|
2005-07-07 |
2014-10-28 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
|
ES2708763T3
(es)
|
2005-07-07 |
2019-04-11 |
Seattle Genetics Inc |
Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
|
EP4026840A1
(en)
|
2005-07-18 |
2022-07-13 |
Seagen Inc. |
Beta-glucuronide-linker drug conjugates
|
NZ572836A
(en)
|
2006-05-16 |
2011-12-22 |
Pharmascience Inc |
Iap bir domain binding compounds
|
WO2007143600A2
(en)
*
|
2006-06-05 |
2007-12-13 |
Incyte Corporation |
Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
|
US20080020979A1
(en)
*
|
2006-06-09 |
2008-01-24 |
Rapraeger Alan C |
Peptides of Syndecan-1 For Inhibiting Angiogenesis
|
WO2008130217A1
(en)
*
|
2006-08-08 |
2008-10-30 |
Applied Nanosystems B.V. |
Cyclic angiotensin analogs
|
US8455622B2
(en)
|
2006-12-01 |
2013-06-04 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
RS52305B
(en)
|
2007-07-16 |
2012-12-31 |
Genentech Inc. |
ANTI-CD79B ANTIBODIES AND IMMUNOCONCULATES AND METHODS OF USE
|
PE20090481A1
(es)
|
2007-07-16 |
2009-05-18 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
|
CA2697992C
(en)
|
2007-10-04 |
2017-08-22 |
Zymogenetics, Inc. |
B7 family member zb7h6 and related compositions and methods
|
EP3115469B1
(en)
|
2007-11-19 |
2020-04-29 |
Celera Corporation |
Lung cancer markers and uses thereof
|
KR20100107501A
(ko)
|
2008-01-18 |
2010-10-05 |
메디뮨 엘엘씨 |
부위 특이적 접합을 위한 시스테인 조작 항체
|
ES2587392T3
(es)
|
2008-01-31 |
2016-10-24 |
Genentech, Inc. |
Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
|
CN102076865B
(zh)
|
2008-05-02 |
2016-03-16 |
西雅图基因公司 |
用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
|
WO2011005481A1
(en)
|
2009-06-22 |
2011-01-13 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
EA030827B1
(ru)
|
2009-10-23 |
2018-10-31 |
Милленниум Фармасьютикалз, Инк. |
Анти-gcc антитело и его применения
|
JP2013513380A
(ja)
|
2009-12-09 |
2013-04-22 |
アンスティテュー・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル・(イ・エヌ・エス・ウ・エール・エム) |
B7h6と結合するモノクローナル抗体およびその使用
|
WO2011097627A1
(en)
|
2010-02-08 |
2011-08-11 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to 161p2f10b proteins
|
SG182724A1
(en)
|
2010-02-12 |
2012-08-30 |
Pharmascience Inc |
Iap bir domain binding compounds
|
SI3178851T1
(sl)
|
2010-03-31 |
2020-09-30 |
Boehringer Inhelheim International Gmbh |
Anti-CD40 protitelesa
|
AU2011312417B2
(en)
|
2010-09-29 |
2015-08-20 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
|
TWI545134B
(zh)
|
2010-10-22 |
2016-08-11 |
西雅圖遺傳學公司 |
以奧裡斯他汀(AURISTATIN)為主之抗體藥物結合物及PI3K-AKT mTOR路徑抑制劑間的協同功效
|
US9421274B2
(en)
|
2011-05-16 |
2016-08-23 |
Koninklijke Philips N.V. |
Bio-orthogonal drug activation
|
US9127065B2
(en)
|
2011-05-19 |
2015-09-08 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Anti-human HER3 antibodies and uses thereof
|
BR112013031819B1
(pt)
|
2011-06-10 |
2022-05-03 |
Mersana Therapeutics, Inc |
Suporte polimérico, composição farmacêutica, composto, e, uso do suporte
|
US9409988B2
(en)
|
2011-06-22 |
2016-08-09 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-Axl antibodies and uses thereof
|
US9249228B2
(en)
|
2011-06-22 |
2016-02-02 |
Oribase Pharma |
Anti-Axl antibodies and uses thereof
|
CA2852860C
(en)
|
2011-11-17 |
2020-06-09 |
Matthew David DOROSKI |
Cytotoxic peptides and antibody drug conjugates thereof
|
US11147852B2
(en)
|
2011-12-23 |
2021-10-19 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
WO2013109994A1
(en)
|
2012-01-20 |
2013-07-25 |
Sea Lane Biotechnologies, Llc |
Surrobody cojugates
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
WO2013174783A1
(en)
|
2012-05-23 |
2013-11-28 |
Pieris Ag |
Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
|
ES2718478T3
(es)
|
2012-06-08 |
2019-07-02 |
Sutro Biopharma Inc |
Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
|
WO2013192360A1
(en)
|
2012-06-19 |
2013-12-27 |
Ambrx, Inc. |
Anti-cd70 antibody drug conjugates
|
US9732161B2
(en)
|
2012-06-26 |
2017-08-15 |
Sutro Biopharma, Inc. |
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
SG11201501286PA
(en)
|
2012-08-23 |
2015-05-28 |
Agensys Inc |
Antibody drug conjugates (adc) that bind to 158p1d7 proteins
|
AU2013308494B2
(en)
|
2012-08-31 |
2018-03-01 |
Sutro Biopharma, Inc. |
Modified amino acids comprising an azido group
|
EP2922574B1
(en)
|
2012-11-22 |
2023-05-17 |
Tagworks Pharmaceuticals B.V. |
Chemically cleavable group
|
AU2013359506B2
(en)
|
2012-12-10 |
2018-05-24 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
EP2931316B1
(en)
|
2012-12-12 |
2019-02-20 |
Mersana Therapeutics, Inc. |
Hydroxyl-polymer-drug-protein conjugates
|
AU2014240012A1
(en)
|
2013-03-15 |
2015-09-24 |
Abbvie Inc. |
Antibody drug conjugate (ADC) purification
|
SI2968588T1
(sl)
|
2013-03-15 |
2019-05-31 |
AbbVie Deutschland GmbH & Co. KG |
Formulacije konjugatov protitelo proti-EGFR zdravilo
|
WO2015006555A2
(en)
|
2013-07-10 |
2015-01-15 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
US9925273B2
(en)
|
2013-08-01 |
2018-03-27 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to CD37 proteins
|
CN105764924A
(zh)
|
2013-09-12 |
2016-07-13 |
哈洛齐梅公司 |
修饰的抗表皮生长因子受体抗体及其使用方法
|
JP6420331B2
(ja)
|
2013-10-11 |
2018-11-07 |
メルサナ セラピューティクス,インコーポレイティド |
タンパク質−高分子−薬剤コンジュゲート
|
WO2015054691A2
(en)
|
2013-10-11 |
2015-04-16 |
The United States Of America, As Pepresented By The Secretary, Department Of Health And Human Services |
Tem8 antibodies and their use
|
EP3055298B1
(en)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
MX2016004659A
(es)
|
2013-10-11 |
2017-08-02 |
Asana Biosciences Llc |
Conjugados proteina-polimero-farmaco.
|
US9644037B2
(en)
|
2013-10-18 |
2017-05-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use
|
EP3066118B1
(en)
|
2013-11-06 |
2020-01-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
MX2016005854A
(es)
|
2013-11-07 |
2017-07-28 |
Inserm (Institut Nat De La Santé Et De La Rech Médicale) |
Anticuerpo anti-her3 alosterico de la neuregulina.
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
EP3094350B1
(en)
|
2014-01-15 |
2020-03-04 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Cartilage targeting agents and their use
|
UY36041A
(es)
|
2014-03-21 |
2015-09-30 |
Abbvie Inc |
Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
|
FR3020063A1
(fr)
|
2014-04-16 |
2015-10-23 |
Gamamabs Pharma |
Anticorps humain anti-her4
|
CN106999578B
(zh)
|
2014-07-31 |
2022-03-04 |
美国政府(由卫生和人类服务部的部长所代表) |
针对epha4的人类单克隆抗体和其用途
|
EP3262071B8
(en)
|
2014-09-23 |
2022-05-18 |
F. Hoffmann-La Roche AG |
Method of using anti-cd79b immunoconjugates
|
WO2016130969A1
(en)
|
2015-02-13 |
2016-08-18 |
George Robert Pettit |
Silstatin compounds
|
EP3261665A1
(en)
|
2015-02-24 |
2018-01-03 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
UA122331C2
(uk)
|
2015-03-09 |
2020-10-26 |
Едженсіс, Інк. |
Антитіло проти flt3 та кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком flt3
|
EP3091033A1
(en)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3 antibodies and uses thereof
|
US10591465B2
(en)
|
2015-05-12 |
2020-03-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for labeling, detection and isolation of Foxp3+ regulatory T cells, isolated population of Foxp3+ regulatory T cells thus obtained and uses thereof
|
ES2898023T3
(es)
|
2015-05-22 |
2022-03-03 |
Inst Nat Sante Rech Med |
Fragmentos de anticuerpos monoclonales humanos que inhiben tanto la actividad catalítica de Cath-D como su unión al receptor LRP1
|
US20180134788A1
(en)
|
2015-05-26 |
2018-05-17 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and Pharmaceutical Compositions (NTSR1 Inhibitors) for the Treatment of Hepatocellular Carcinomas
|
WO2016189118A1
(en)
|
2015-05-28 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
|
JP7269733B2
(ja)
|
2015-06-12 |
2023-05-09 |
レンティジェン・テクノロジー・インコーポレイテッド |
操作されたt細胞を用いて癌を処置するための方法
|
US10392441B2
(en)
|
2015-10-07 |
2019-08-27 |
United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
|
EP3359562B1
(en)
|
2015-10-09 |
2019-12-04 |
Miltenyi Biotec Technology, Inc. |
Chimeric antigen receptors and methods of use
|
US10556953B2
(en)
|
2015-10-12 |
2020-02-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction
|
KR20180104106A
(ko)
|
2016-01-27 |
2018-09-19 |
서트로 바이오파마, 인크. |
anti-CD74 항체 접합체, anti-CD74 항체 접합체를 포함하는 조성물 및 anti-CD74 항체 접합체의 이용 방법
|
EP3419655A1
(en)
|
2016-02-27 |
2019-01-02 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Peptide vaccines comprising self-assembling polymer nanoparticles
|
EP3791897A1
(en)
|
2016-02-29 |
2021-03-17 |
Madrigal Pharmaceuticals, Inc. |
Hsp90 inhibitor drug conjugates
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
EP3433278A4
(en)
|
2016-03-25 |
2019-11-06 |
Seattle Genetics, Inc. |
PROCESS FOR THE PREPARATION OF PEGYLATED MEDICINE LINKS AND INTERMEDIATES THEREOF
|
CN109562169A
(zh)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
抗cd98抗体及抗体药物偶联物
|
WO2017214339A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
WO2017214322A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
CN116284404A
(zh)
|
2016-06-08 |
2023-06-23 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
AU2017277916A1
(en)
|
2016-06-08 |
2019-01-03 |
Abbvie Inc. |
Anti-CD98 antibodies and antibody drug conjugates
|
US11617799B2
(en)
|
2016-06-27 |
2023-04-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
CN109843922B
(zh)
|
2016-09-02 |
2023-10-03 |
莱蒂恩技术公司 |
用DuoCAR治疗癌症的组合物和方法
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
EP3565830B1
(en)
|
2017-01-09 |
2021-03-10 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-mesothelin immunotherapy
|
US11730822B2
(en)
|
2017-03-24 |
2023-08-22 |
Seagen Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
WO2018175988A1
(en)
|
2017-03-24 |
2018-09-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd33 immunotherapy
|
US11932694B2
(en)
|
2017-04-19 |
2024-03-19 |
Bluefin Biomedicine, Inc. |
Anti-VTCN1 antibodies and antibody drug conjugates
|
AU2018290330A1
(en)
|
2017-06-22 |
2020-01-02 |
Mersana Therapeutics, Inc. |
Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
|
EP3658588A1
(en)
|
2017-07-26 |
2020-06-03 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
AU2018309735A1
(en)
|
2017-07-31 |
2020-02-20 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
|
JP7035170B2
(ja)
|
2017-09-15 |
2022-03-14 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗cd19免疫療法によりがんを処置するための組成物および方法
|
JP7423513B2
(ja)
|
2017-09-18 |
2024-01-29 |
ストロ バイオファーマ インコーポレーテッド |
抗葉酸受容体α抗体コンジュゲート及びその使用
|
WO2019079249A1
(en)
|
2017-10-16 |
2019-04-25 |
Lentigen Technology, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-CD22 IMMUNOTHERAPY
|
WO2019094709A1
(en)
|
2017-11-09 |
2019-05-16 |
Pettit George R |
Betulastatin compounds
|
US10894819B2
(en)
|
2017-12-20 |
2021-01-19 |
Lentigen Technology, Inc. |
Compositions and methods for treating HIV/AIDS with immunotherapy
|
US20210299286A1
(en)
|
2018-05-04 |
2021-09-30 |
Tagworks Pharmaceuticals B.V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
US20210308207A1
(en)
|
2018-05-04 |
2021-10-07 |
Tagworks Pharmaceuticals B.V. |
Compounds comprising a linker for increasing transcyclooctene stability
|
US20210261678A1
(en)
|
2018-06-29 |
2021-08-26 |
Boehringer Ingelheim International Gmbh |
Anti-cd40 antibodies for use in treating autoimmune disease
|
CA3104142A1
(en)
|
2018-07-11 |
2020-01-16 |
Timothy Clyde GRANADE |
Monoclonal antibody for the detection of the antiretroviral drug emtricitabine (ftc, 2',3'-dideoxy-5-fluoro-3'-thiacytidine)
|
US20220047716A1
(en)
|
2018-09-17 |
2022-02-17 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
WO2020061498A1
(en)
|
2018-09-20 |
2020-03-26 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd123 immunotherapy
|
CN113286607A
(zh)
|
2018-09-26 |
2021-08-20 |
莱蒂恩技术公司 |
用于用抗cd19/cd22免疫治疗来治疗癌症的组合物和方法
|
MX2021004906A
(es)
|
2018-10-29 |
2021-09-10 |
Mersana Therapeutics Inc |
Conjugados de anticuerpo modificado con cisteína-fármaco con enlazadores que contienen péptidos.
|
US11103533B2
(en)
|
2018-11-30 |
2021-08-31 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD38 immunotherapy
|
EP3898699A1
(en)
|
2018-12-19 |
2021-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
|
CN113924103A
(zh)
|
2019-03-06 |
2022-01-11 |
莱蒂恩技术公司 |
用于用自驱动的嵌合抗原受体来治疗癌症的组合物和方法
|
US20220362394A1
(en)
|
2019-05-03 |
2022-11-17 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
CN114364801B
(zh)
|
2019-05-30 |
2024-04-19 |
莱蒂恩技术公司 |
用于用抗bcma免疫治疗来治疗癌症的组合物和方法
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
WO2020256546A1
(en)
|
2019-06-17 |
2020-12-24 |
Tagworks Pharmaceuticals B.V. |
Compounds for fast and efficient click release
|
CA3142833A1
(en)
|
2019-07-02 |
2021-01-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind egfrviii and their use
|
EP3812008A1
(en)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-competitive antagonist antibody
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
US20230095053A1
(en)
|
2020-03-03 |
2023-03-30 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
AU2021296423A1
(en)
|
2020-06-22 |
2023-02-02 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
|
EP4213939A1
(en)
|
2020-09-21 |
2023-07-26 |
Boehringer Ingelheim International GmbH |
Use of anti-cd40 antibodies for treatment of inflammatory conditions
|
EP4240397A1
(en)
|
2020-11-05 |
2023-09-13 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
KR20230146032A
(ko)
|
2021-02-15 |
2023-10-18 |
다케다 야쿠힌 고교 가부시키가이샤 |
Tgf-b 신호전달을 조절하기 위한 세포 치료 조성물 및 방법
|
JP2024519205A
(ja)
|
2021-04-30 |
2024-05-09 |
セルジーン コーポレーション |
抗bcma抗体薬物コンジュゲート(adc)をガンマセクレターゼ阻害剤(gsi)と組み合わせて使用する併用療法
|
CA3221281A1
(en)
|
2021-06-29 |
2023-01-05 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
JPWO2023033129A1
(es)
|
2021-09-03 |
2023-03-09 |
|
|
WO2023031445A2
(en)
|
2021-09-06 |
2023-03-09 |
Veraxa Biotech Gmbh |
Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
|
EP4186529A1
(en)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
WO2023094525A1
(en)
|
2021-11-25 |
2023-06-01 |
Veraxa Biotech Gmbh |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
WO2023104941A1
(en)
|
2021-12-08 |
2023-06-15 |
European Molecular Biology Laboratory |
Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
|
EP4372000A2
(en)
|
2022-02-15 |
2024-05-22 |
Tagworks Pharmaceuticals B.V. |
Masked il12 protein
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
WO2024006542A1
(en)
|
2022-06-30 |
2024-01-04 |
Sutro Biopharma, Inc. |
Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
|
WO2024013723A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody drug conjugates that bind cdcp1 and uses thereof
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
US20240075142A1
(en)
|
2022-08-26 |
2024-03-07 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy
|
WO2024080872A1
(en)
|
2022-10-12 |
2024-04-18 |
Tagworks Pharmaceuticals B.V. |
Strained bicyclononenes
|